FR2936255B1 - Modulateurs de fzd2 dans le traitement de l'alopecie - Google Patents

Modulateurs de fzd2 dans le traitement de l'alopecie

Info

Publication number
FR2936255B1
FR2936255B1 FR0856315A FR0856315A FR2936255B1 FR 2936255 B1 FR2936255 B1 FR 2936255B1 FR 0856315 A FR0856315 A FR 0856315A FR 0856315 A FR0856315 A FR 0856315A FR 2936255 B1 FR2936255 B1 FR 2936255B1
Authority
FR
France
Prior art keywords
alopecia
treatment
fzd2
modulators
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0856315A
Other languages
English (en)
Other versions
FR2936255A1 (fr
Inventor
Sandrine Rethore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR0856315A priority Critical patent/FR2936255B1/fr
Priority to US13/120,103 priority patent/US20110224243A1/en
Priority to EP09747890A priority patent/EP2329036A1/fr
Priority to CA2737993A priority patent/CA2737993A1/fr
Priority to PCT/FR2009/051770 priority patent/WO2010031979A1/fr
Publication of FR2936255A1 publication Critical patent/FR2936255A1/fr
Application granted granted Critical
Publication of FR2936255B1 publication Critical patent/FR2936255B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FR0856315A 2008-09-19 2008-09-19 Modulateurs de fzd2 dans le traitement de l'alopecie Expired - Fee Related FR2936255B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0856315A FR2936255B1 (fr) 2008-09-19 2008-09-19 Modulateurs de fzd2 dans le traitement de l'alopecie
US13/120,103 US20110224243A1 (en) 2008-09-19 2009-09-21 FZD2 Molulators in the Treatment of Alopecia
EP09747890A EP2329036A1 (fr) 2008-09-19 2009-09-21 Modulateurs de fzd2 dans le traitement de l'alopecie
CA2737993A CA2737993A1 (fr) 2008-09-19 2009-09-21 Modulateurs de fzd2 dans le traitement de l'alopecie
PCT/FR2009/051770 WO2010031979A1 (fr) 2008-09-19 2009-09-21 Modulateurs de fzd2 dans le traitement de l'alopecie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0856315A FR2936255B1 (fr) 2008-09-19 2008-09-19 Modulateurs de fzd2 dans le traitement de l'alopecie

Publications (2)

Publication Number Publication Date
FR2936255A1 FR2936255A1 (fr) 2010-03-26
FR2936255B1 true FR2936255B1 (fr) 2010-10-15

Family

ID=40568269

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0856315A Expired - Fee Related FR2936255B1 (fr) 2008-09-19 2008-09-19 Modulateurs de fzd2 dans le traitement de l'alopecie

Country Status (5)

Country Link
US (1) US20110224243A1 (fr)
EP (1) EP2329036A1 (fr)
CA (1) CA2737993A1 (fr)
FR (1) FR2936255B1 (fr)
WO (1) WO2010031979A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827287B (zh) 2005-10-31 2015-08-12 昂考梅德药品有限公司 用于诊断和治疗癌症的组合物和方法
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5792621B2 (ja) 2008-09-26 2015-10-14 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
US8551789B2 (en) 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
AU2012271413B2 (en) 2011-06-17 2017-07-13 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
WO2014121196A1 (fr) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Méthodes et surveillance de traitement par un inhibiteur de la voie wnt
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5301201A (en) * 2000-03-31 2001-10-15 Gen Hospital Corp Methods of modulating hair growth
WO2005084223A2 (fr) * 2004-02-27 2005-09-15 The General Hospital Corporation Procedes et compositions pour la croissance capillaire

Also Published As

Publication number Publication date
EP2329036A1 (fr) 2011-06-08
CA2737993A1 (fr) 2010-03-25
US20110224243A1 (en) 2011-09-15
WO2010031979A1 (fr) 2010-03-25
FR2936255A1 (fr) 2010-03-26

Similar Documents

Publication Publication Date Title
FR2936255B1 (fr) Modulateurs de fzd2 dans le traitement de l'alopecie
Lehoczky et al. Lgr6 marks nail stem cells and is required for digit tip regeneration
MX2021004410A (es) Inhibidores de la proteina tirosina fosfatasa.
Nakata et al. Emerging role for leucine-rich repeat-containing G-protein-coupled receptors LGR5 and LGR4 in cancer stem cells
BR112021018664A2 (pt) Inibidores de proteína tirosina fosfatase
MA29330B1 (fr) Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires.
MA34771B1 (fr) Formes cristallines
MA35096B1 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
MA29851B1 (fr) Composes et compositions contenant de la diarylamine et utilisation en tant que modulateurs de recepteurs de c-kit
IL221366A0 (en) SOLUBLE zB7RI POLYPEPTIDE AND METHOD USING IT
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
AR079641A1 (es) Compuestos para el diagnostico por imagenes de la muerte de las celulas por apotosis
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
MA32797B1 (fr) Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one
WO2010036960A3 (fr) Procédés pour traiter, diagnostiquer, et surveiller le lupus
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
MA33839B1 (fr) Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs
WO2012103165A3 (fr) Anticorps anti-kit et leurs utilisations
EP3839068A3 (fr) Procédés pour traiter, diagnostiquer, et surveiller le lupus
ATE415632T1 (de) Verfahren zur diagnose und behandlung von morbus crohn
ATE433115T1 (de) Timp-2 als ziel/marker des versagens von beta- zellen
EA201290534A1 (ru) Бициклические тиазолы в качестве аллостерических модуляторов mglur5 рецепторов
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
FR2930036B1 (fr) Procede de diagnostic d'une hypertension arterielle pulmonaire.
ES2570609T3 (es) Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20130531